MD and professor at Institute for Clinical Medicine, Aarhus University Denmark, Eskild Petersen gives an overview and share his thoughts about the pandemic.

Read about the susceptibility and severity of COVID-19 described from the human genome, managent of ADHD during the pandemic and gastrointestinal involvement in patients with COVID-19. 

Current considerations regarding options for management of women with gynecologic cancers in the time of the COVID-19 pandemic. 

MEST SETE MEDtalks

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer   Se hele webinar

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/asco-2019-breakthrough-for-cdk4-6-inhibitor-endocrine-therapy-in-premenopausal-patients-with-hr-her2%e2%88%92-advanced-breast-cancer/'>Se hele webinar
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

<script src="https://fast.wistia.com/embed/medias/rp2kqsxgnz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rp2kqsxgnz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rp2kqsxgnz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/asco-2019-updated-overall-survival-for-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer/'>Se hele webinar
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/eha-2019-venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities/'>Se hele webinar
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients&nbsp;&nbsp;&nbsp;<a href='https://bpno.se/webinar/eha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patientseha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patients/'>Se hele webinar
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

Many general practitioners and dermatologists have reported an increased incidence of severe hand eczema during the COVID-19 pandemic.

Patient with pulmonary adenocarcinoma undergoing concomitant chemoradiotherapy was tested positive for SARS-CoV-2 and died shortly from respiratory failure.

Oxygen therapy is a central medicine for the severely ill patient. However it should be used with clear indications and precautions. 

#Senaste Tidskrift

Dermatologi

Nr. 1 • mars 2020
Årgång 11
  • Malignt melanom
  • Atopisk dermatit
  • Allergi